Literature DB >> 12067299

Human proteinase 3 can inhibits LPS-mediated TNF-alpha production through CD14 degradation: lack of influence of antineutrophil cytoplasmic antibodies.

B A Yard1, A-I Wille, M Haak, F J van der Woude.   

Abstract

The present study was conducted to investigate if proteinase-3 (PR3) is able to influence lipopolysaccharide (LPS) responses of monocytes via degradation of CD14 and if antineutrophil cytoplasmic antibodies (ANCA) may modify this process. Recombinant (r) CD14 and CD14 expressed on monocytes were investigated for PR3 mediated degradation by SDS-PAGE and FACS analysis, respectively. TNF-alpha production in whole blood was used to determine functional consequences of CD14 degradation. PR3 degraded rCD14 in a dose- and time-dependent fashion. Major degradation products were found with apparent molecular weight of 45, 25 and 10 kDa. Treatment of PR3 with PMSF completely abolished CD14 degradation. ANCA IgG did not inhibit CD14 degradation. In whole blood, addition of PR3 resulted in diminished CD14 expression on monocytes. In contrast, CD14 was increased in a subpopulation of cells that expressed major histocompatibility (MHC) class II and PR3, but lacked expression of CD64 and CD16. LPS mediated TNF-alpha production in whole blood was significantly inhibited when preincubated with PR3. This study demonstrates that PR3 can degrade rCD14 and that PR3 differentially affects CD14 expression in subsets of monocytes. ANCA IgG does not play a significant role herein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067299      PMCID: PMC1906262          DOI: 10.1046/j.1365-2249.2002.01877.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.

Authors:  G Gaskin; C O Savage; J J Ryan; S Jones; A J Rees; C M Lockwood; C D Pusey
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

Review 2.  CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy.

Authors:  J E Scherberich; W A Nockher
Journal:  Clin Chem Lab Med       Date:  1999-03       Impact factor: 3.694

3.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

Authors:  C Coeshott; C Ohnemus; A Pilyavskaya; S Ross; M Wieczorek; H Kroona; A H Leimer; J Cheronis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation.

Authors:  K Le-Barillec; M Si-Tahar; V Balloy; M Chignard
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

6.  Bacterial cell envelopes (ghosts) but not S-layers activate human endothelial cells (HUVECs) through sCD14 and LBP mechanism.

Authors:  S Fürst-Ladani; H Redl; A Haslberger; W Lubitz; P Messner; U B Sleytr; G Schlag
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

7.  ANCA and predicting relapse in systemic vasculitis.

Authors:  D R Jayne; G Gaskin; C D Pusey; C M Lockwood
Journal:  QJM       Date:  1995-02

8.  Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3.

Authors:  R W Leid; B E Ballieux; I van der Heijden; C Kleyburg-van der Keur; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

9.  Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.

Authors:  C A Stegeman; J W Tervaert; W J Sluiter; W L Manson; P E de Jong; C G Kallenberg
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

10.  Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3.

Authors:  M Padrines; M Wolf; A Walz; M Baggiolini
Journal:  FEBS Lett       Date:  1994-09-26       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.